FIELD: chemistry.
SUBSTANCE: (E)-2-(5-Chlorothiene-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl} ethensulfonamide in essentially crystal form has powder radiograph, expressed in angle values 20, and obtained by means of difractometer, including peaks, located in the following positions expressed in angles 2θ: 9.1-9.2 (±0.1), 16.0-16.1(±0.1), 18.0-18.2 (±0.1) and 18.3-18.4 (±0.1) degrees, and term "essentially crystal form" means that said form is mainly free from amorphous form of (E)-2-(5-Chlorothiene-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl} ethensulfonamide, and by term "mainly free from" content of amorphous form less than 50% is meant.
EFFECT: increased activity.
15 cl, 2 dwg, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRROLIDINE-2-ONES AS INHIBITORS OF XA FACTOR | 2002 |
|
RU2318807C2 |
| (S)-(-)-AMLODIPINE CAMSYLATE OR ITS HYDRATE AND PHARMACEUTICAL COMPOSITION INCLUDING THEM | 2007 |
|
RU2403241C1 |
| CRYSTALLINE DERIVATIVES OF 1-METHYLCARBAPENEM | 2000 |
|
RU2214411C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| NONHYGROSCOPIC CRYSTALLINE 5-[(Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[(2S)-2-HYDROXY-3-MORPHOLIN-4-YLPROPYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALEATE SALT, PHARMACEUTICAL COMPOSITION AND METHOD FOR CANCER TREATMENT | 2004 |
|
RU2319702C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| PRODUCTION METHOD AND INTERMEDIATE PRODUCTS FOR PRODUCTION OF PYRROLO[2,3-D]PYRIMIDINE, AND ITS USE | 2019 |
|
RU2780482C2 |
| NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2786722C1 |
| AMINE SOLVATE OF SODIUM GLUCOSE OPENER OF SODIUM GLUCOSE OPENER AND METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2710230C1 |
| NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2820150C2 |
